London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...
US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...
The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...
Everyone is talking about or using weight loss products. So, the government pounces. A batch of 17 drugs are on a list of ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
22h
Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations ...
Among those with chronic medical conditions, a third (33 percent) either had no concerns about developing shingles or were ...
The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...
Immunoglobulin G hypogammaglobulinemia was found in 44.7% of patients with acute exacerbations of COPD receiving triple ...
US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively ...
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback